Clinical potential of cyclo-oxygenase-2 inhibitors

BioDrugs

Volumn 15, Issue 9, 2001, Pages 563-572

  Ouiedo, Jaime A ^a   Michael Wolfe, M ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IBUPROFEN; INDOMETACIN; LIPOXYGENASE; MELOXICAM; MEMBRANE PHOSPHOLIPID; MESSENGER RNA; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A1; ROFECOXIB;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; FEMALE INFERTILITY; GASTRODUODENAL ULCER; GASTROINTESTINAL POLYPOSIS; GASTROINTESTINAL SYMPTOM; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOSIS;

EID: 0034771469     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/00063030-200115090-00001     Document Type: Review

References (76)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99
2. Douthwaite AH, Lintott GAM. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet 1938; 2: 1222-5
3. Sun DC, Roth SH, Mitchell CS, et al. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis 1974; 19: 40510
4. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic ulcer disease: a report from the Boston Collaborative Drug Surveillance program, Boston University Medical Center. N Engl J Med 1974; 290: 1158-62
5. SilvosoGR, Ivey KJ, Butt JH, etal. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91: 517-20
6. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9
7. Hunt RH. A symposium on COX-2 inhibitors. Am J Med 1999; 107(6A): 1S-2S
8. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcération. Gut 1987; 28: 527-32
9. Fries JF, Singh G, Ramey DR. The clinical epidemiology of nonsteroidal anti-inflammatory drug gastropathy in clinical significance and potential of selective COX-2 inhibitors. In: Vane J, Bolting R, editors. Clinical significance: potential of selective COX-2 inhibitors; London: William Havery Press, 1998;57-66
10. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5
11. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971 ; 231: 2357
12. McKenna F. COX-2: separating myth from reality. Scand J Rheumatol 1999; 28 Suppl. 109: 19-29
13. Seibert K, Masferrer JL, Fu JY, et al. The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. Adv Prostaglandin Thromboxane Leukit Res 1991 ; 21:45-51
14. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sei U S A 1991 ; 88: 2692-6
15. O'Banion MK, Sadowski HB, Winn V, et al. A serum and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 23261-7
16. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a new prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266: 12866-72
17. Vane J. Towards a better aspirin. Nature 1994; 367: 215-6
18. Wolfe MM. Future trends in the development of safer nonsteroidal anti-inflammatory drugs. Am J Med 1998; 105 (5A): 44S-52S
19. Wallace JL. Distribution and expression of COX isoenzymes, their physiological roles and the categorization of NSAIDs. Am J Med 1999; 107 (6A): 11S-17S
20. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14
21. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical applications of specific cyclooxigenase-2 inhibitors. Arthritis Rheum 2000; 43 (1): 4-20
22. Siegle I, Klein T, Backman JT, et al. Expression of COX-1 and COX-2 in human synovial tissue: differential elevation of COX-2 in inflammatory joint diseases. Arthritis Rheum 1998; 41: 122-9
23. Smith CJ, Zhang Y, Kiboldt CM, et al. Pharmacological analysis of COX-1 in inflammation. Proc Natl Acad Sei U S A 1998; 95: 13313-8
24. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of COX-2 in inflammation and pain. Proc Natl Acad Sei U S A 1994; 91: 12013-7
25. Cao C, Matsumura K, Yamagata K, et al. Induction by lipopolysaccharide of COX-2 mRNA in rat brain; its possible role in the febrile response. Brain Res 1999; 825: 86-94
26. Singer I, Kawka DW. Schloeman S, et al. COX-2 is induced in colonie epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115: 297-306
27. McCarthy CJ, Crofford LJ, Greensom J, et al. COX-2 expression in gastric antrat mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1218-23
28. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of COX-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112:387-97
29. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonie injury in rat through inhibition of COX-2. J Clin Invest 1996; 98: 2076-85
30. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73
31. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APCd716 knockout mice by inhibition of COX-2. Cell 1996; 87: 803-9
32. Tsuji M, DuBois RN. Alterations in cellular adhesions and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501
33. Tsujii M, Kawano S, Tsujii S, et al. Cyclooxygenase regulated angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16
34. PDA. Celecoxib: summary of clinical trials and prescribing information [online]. Available for URL: http://www.fda.gov/ cder/foi/appletter/1998/209981tr.pdf. [Accessed 2001 Feb 1[
35. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs NSAIDs for osteoarthritis and rheumatoid arthritis. The CLASS study (Celecoxib long term arthritis safety study). JAMA 2000; 284: 1247-55
36. Feldman M, McMahon AT. Do COX-2 inhibitors provide benefits similar to those of traditional NSAIDs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43
37. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282 1821-8
38. Lichtenstein DR. Wolfe MM. COX-2-selective NSAIDs. New and improved? JAMA 2000; 284: 1297-9
39. Geis S, Hubbard R, Callison D, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41 (9 Suppl.): S364
40. Hubbard R, Geis S, Woods E, et al. Efficacy, tolerability and safety of celecoxib, a specific COX-2 inhibitor in osteoarthritis [abstract]. Arthritis Rheum 1998; 41 (9 Suppl.): S196
41. Geis S, Stead H, Morant S, et al. Efficacy and safety of celecoxib, a specific COX-2 inhibitor in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41 (9 Suppl.): S316
42. Goldstein JL, Agrawal NM, Silverstein F. et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal events in osteoarthritis and rheumatoid arthritis as compared to NSAIDs [abstract]. Gastroenterology 1999; 116: A174
43. Rofecoxib for osteoarthritis and pain. Med Lett Drugs Ther 1999; 41: 59-61
44. Rofecoxib product literature. West Point (PA): Merck & Co Inc., 1999
45. Wight NJ, Gottesdiener K, Garlick NM, et al. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 2001; 120: 86773
46. Cannon G, Caldwell J, Holt P. et al. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26-week controlled trial [abstract]. Arthritis Rheum 1998;41 (9Suppl.):S196
47. Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy compared to ibuprofen in the treatment of hip and knee osteoarthritis in a 6-week controlled trial [abstract]. Arthritis Rheum 1998; 41 (9 Suppl.): S196
48. Brown J, Morrison BW, Bitner M, et al. The COX-2 specific inhibitor MK-0966, is effective in the treatment of primary dysmenorrhea [abstract]. Clin Pharmacol Ther 1999; 65: 118
49. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib a COX-2 inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83
50. Langman M, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAlDs. JAMA 1999; 282: 1929-33
51. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
52. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxigenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol ExpTher 1994; 271: 1705
53. Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281: 107
54. Inman HW. Wilton LV, Pearce GL, et al. Prescription-event monitoring of nabumetone. Pharmaceut Med 1990; 4: 309-17
55. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999; 107: 6A: 48S-54S
56. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565-71
57. Lanza F, Rack MF, Lynn M, et al. An endoscopie comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen and placebo on the gastrointestinal mucosa. J Rheumatol 1987; 14:338-41
58. Neustadt DH. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol 1997; 24 Suppl. 47: 17-22
59. Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with rheumatoid arthritis or osteoarthritis and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol 1991; 18 Suppl. 28: 11-4
60. PDA. Review of serious GI adverse events: etodolac [transcript]. 1990Sep20
61. Beejay U, Wolfe MM. COX-2 selective inhibitors: panacea or flash in the pan. Gastroenterology 1999; 117: 1002-5
62. Barrison AF, Wolfe MM. Management of NSAID-related gastrointestinal mucosal injury. Inflammopharmacology 1999; 3: 277-86
63. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635. a novel COX-2 inhibitor: efficacy and safety in two placebo controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-602
64. Dubois RN, Radhika A, Reddy BS, et al. Increased COX-2 levels in carcinogen-induced rat colonie tumors. Gastroenterology 1996; 110: 1259-62
65. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Ape Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-4
66. Chulada PC, Doyle C, Gaul B, et al. COX-1 and 2 deficiency decreases spontaneous intestinal adenomas in the min mouse. Proc Am Assoc Cancer Res 1998; 39: 195
67. Yoshimi N, Kawabata K, Hara A, et al. Inhibitory effect of NS-398, a selective COX-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997; 88: 1044-51
68. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific COX-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12
69. Gideon S, Lynch PM, Robin KS, et al. The effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52
70. Swan SK, Rudy DW, Lasseter KC, et al. Effect of COX-2 inhibition on renal function in elderly persons receiving a low salt diet. Ann Intern Med 2000; 133: 1-9
71. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160: 913-20
72. Tocco G, Freire-Moar J, Schreiber SS, et al. Maturational regulation and regional induction of COX-2 in rat brain: impli-cations for Alzheimer's disease. Exp Neurol 1997; 144 33949
73. Breitner JCS. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996;47:401-11
74. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-32
75. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by COX-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sei USA1999;96:272-7
76. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 296: 954-9